66
Participants
Start Date
May 27, 2016
Primary Completion Date
December 19, 2017
Study Completion Date
March 6, 2018
ENTO
Tablets administered orally
Placebo
Tablets administered orally
Hospital Universitario Marques de Valdecilla, Santander
Hospital Universitario La Fe, Valencia
Universitatsklinikum Frankfurt, Frankfurt am Main
University of Miami, Miami
Emory University, Atlanta
Loyola University Medical Center, Maywood
University of Kansas Cancer Center, Westwood
Weill Cornell Medical Center, New York
Duke University Medical Center, Durham
Taussig Cancer Institute, Cleveland
Ohio State University, Wexner Medical Center, Columbus
Vanderbilt University, Nashville
Princess Margaret, Toronto
Institut Paoli Calmettes, Marseille
Hopital Saint Louis, Paris
Institut Gustave Roussy, Villejuif
Universitätsklinikum Carl Gustav Carus, Dresden
Universitatsklinikum Hamburg-Eppendorf, Hamburg
Klinikum der Universitaet Regensburg, Regensburg
Pusan National University Hospital, Busan
Samsung Medical Center, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Hospital Universitario Vall d'Hebron, Barcelona
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario Virgen del Rocio, Seville
Hospital Clinico Universitario de Valencia, Valencia
Kings College Hospital NHS Trust, London
St Bartholomew's Hospital, London
Manchester Royal Infirmary, Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY